Skip to Content
Merck
CN

EHU097001

MISSION® esiRNA

targeting human DMBT1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


description

Powered by Eupheria Biotech

Quality Level

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GCCCTTACTACGTGGACCTGAACCAGGACTTGTACGTTCAGGCTGAAATCCTCCATTCTGATGCTGTACTGACCTTGTTTGTGGACACCTGCGTGGCATCACCATACTCCAATGACTTCACGTCTTTGACTTATGATCTAATCCGGAGTGGATGCGTGAGGGATGACACCTACGGACCCTACTCCTCGCCATCTCTTCGCATTGCCCGCTTCCGGTTCAGGGCCTTCCACTTCCTGAACCGCTTCCCCTCCGTGTACCTGCGTTGTAAAATGGTGGTGTGCAGAGCGTATGACCCCTCTTCCCGCTGCTACCGAGGCTGTGTGTTGAG

Ensembl | human accession no.

shipped in

ambient

storage temp.

−20°C

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany


Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Chao Liang et al.
Nature communications, 10(1), 4579-4579 (2019-10-09)
Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive bone erosion. Leflunomide is originally developed to suppress inflammation via its metabolite A77 1726 to attenuate bone erosion. However, distinctive responsiveness to Leflunomide is observed among RA individuals. Here
S C Chang et al.
Cell death and differentiation, 21(9), 1388-1398 (2014-05-03)
The checkpoint between the life and death of macrophages is crucial for the host's frontline immune defense during acute phase infection. However, the mechanism as to how the immune cell equilibrates between apoptosis and immune response is unclear. Using in



Global Trade Item Number

SKUGTIN
EHU097001-20UG04061828588008
EHU097001-50UG04061828353521